Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

158 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Evaluation of ceftazidime/avibactam for serious infections due to multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa.
Rodríguez-Núñez O, Ripa M, Morata L, de la Calle C, Cardozo C, Fehér C, Pellicé M, Valcárcel A, Puerta-Alcalde P, Marco F, García-Vidal C, Del Río A, Soriano A, Martínez-Martínez JA. Rodríguez-Núñez O, et al. Among authors: ripa m. J Glob Antimicrob Resist. 2018 Dec;15:136-139. doi: 10.1016/j.jgar.2018.07.010. Epub 2018 Jul 20. J Glob Antimicrob Resist. 2018. PMID: 30036695
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis.
Ripa M, Rodríguez-Núñez O, Cardozo C, Naharro-Abellán A, Almela M, Marco F, Morata L, De La Calle C, Del Rio A, Garcia-Vidal C, Ortega MDM, Guerrero-León MLA, Feher C, Torres B, Puerta-Alcalde P, Mensa J, Soriano A, Martínez JA. Ripa M, et al. J Antimicrob Chemother. 2017 Dec 1;72(12):3443-3452. doi: 10.1093/jac/dkx315. J Antimicrob Chemother. 2017. PMID: 28961801
Influence of empirical double-active combination antimicrobial therapy compared with active monotherapy on mortality in patients with septic shock: a propensity score-adjusted and matched analysis-authors' response.
Ripa M, Rodríguez-Nuñez O, Cardozo C, Naharro-Abellán A, Almela M, Marco F, Morata L, De La Calle C, Del Río A, Garcia-Vidal C, Ortega MDM, Guerrero-León MLA, Fehér C, Torres B, Puerta-Alcalde P, Mensa J, Soriano A, Martínez JA. Ripa M, et al. J Antimicrob Chemother. 2018 Jun 1;73(6):1732-1733. doi: 10.1093/jac/dky063. J Antimicrob Chemother. 2018. PMID: 29506238 No abstract available.
Short-Term Peripheral Venous Catheter-Related Bloodstream Infections: Evidence for Increasing Prevalence of Gram-Negative Microorganisms from a 25-Year Prospective Observational Study.
Ripa M, Morata L, Rodríguez-Núñez O, Cardozo C, Puerta-Alcalde P, Hernández-Meneses M, Ambrosioni J, Linares L, Bodro M, Valcárcel A, Casals C, Guerrero-León MLA, Almela M, Garcia-Vidal C, Del Río A, Marco F, Mensa J, Martínez JA, Soriano A. Ripa M, et al. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e00892-18. doi: 10.1128/AAC.00892-18. Print 2018 Nov. Antimicrob Agents Chemother. 2018. PMID: 30126952 Free PMC article.
Ceftobiprole for the treatment of infective endocarditis: A case series.
Tascini C, Attanasio V, Ripa M, Carozza A, Pallotto C, Bernardo M, Francisci D, Oltolini C, Palmiero G, Scarpellini P. Tascini C, et al. Among authors: ripa m. J Glob Antimicrob Resist. 2020 Mar;20:56-59. doi: 10.1016/j.jgar.2019.07.020. Epub 2019 Jul 24. J Glob Antimicrob Resist. 2020. PMID: 31351247 Free article.
The place of ceftazidime/avibactam and ceftolozane/tazobactam for therapy of haematological patients with febrile neutropenia.
Clerici D, Oltolini C, Greco R, Ripa M, Giglio F, Mastaglio S, Lorentino F, Pavesi F, Farina F, Liberatore C, Castiglion B, Tassan Din C, Bernardi M, Corti C, Peccatori J, Scarpellini P, Ciceri F, Castagna A. Clerici D, et al. Among authors: ripa m. Int J Antimicrob Agents. 2021 Jun;57(6):106335. doi: 10.1016/j.ijantimicag.2021.106335. Epub 2021 Apr 7. Int J Antimicrob Agents. 2021. PMID: 33838223
Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection.
Nozza S, Bigoloni A, Calcagno A, Galli L, Pignataro AR, D'Avolio A, Carbone A, Ripa M, Bonora S, Lazzarin A, Castagna A. Nozza S, et al. Among authors: ripa m. J Antimicrob Chemother. 2014 May;69(5):1436-9. doi: 10.1093/jac/dkt530. Epub 2014 Jan 23. J Antimicrob Chemother. 2014. PMID: 24458511 No abstract available.
158 results